Personalized treatment of schizophrenia in everyday clinical practice: reality or fiction?
Each day clinical practice tries to follow the idea and principles of personalized medicine. Besides predicting an individual's sensibility or predisposition for developing schizophrenia, pharmacogenetic and pharmacogenomic approaches attempt to define and acknowledge important indicators of clinical response to antipsychotics namely their efficacy and adverse effects. The main focus of our article were not facts regarding the role CYP450 liver enzymes have in this; our purpose is introducing other, new genetic and epigenetic factors which could introduce important biomarkers in diagnostics of the disease itself, the efficacy and tolerance for antipsychotics. There is still a huge gap between gathering and collecting information and using them for the personalized treatment of schizophrenia. From the genetic point of view personalized treatment of schizophrenia is the field we need to focus on and successfully incorporate it our everyday clinical practice in the future.